TTY Biopharm Co (台灣東洋藥品) yesterday gave an upbeat outlook on its earnings for this year, as the maker of “super generic” drugs further secures its leading position in the manufacture of oncology and anti-infective medicines. The local company is also tapping into the market for multiple sclerosis.
Last month, the Taipei-based company announced that with Netherlands-based 2-BBB Medicines BV, it has established a joint venture company, EnhanX Inc (殷瀚生技).
The joint venture is to develop 2B3-201, a neuro-inflammation treatment initially focused on people with multiple sclerosis (MS) who suffer acute relapses, the company said.
In addition, the partnership is expected to speed up the development and regulatory approval processes, TTY Biopharm said.
TTY Biopharm said that it would leverage its 20-year experience in developing specialized injectable liposomal formulations, as well as microsphere formulations, to control drug release in advancing 2B3-201 through its product pipeline.
The drug is a targeted therapy for MS that is designed to cross the blood-brain barrier — a highly selective semipermeable membrane that separates circulating blood from extracellular fluid in the central nervous system.
Conventional treatments for diseases such as MS require large dosing to penetrate the blood-brain barrier, resulting in severe side effects, the company said.
However, its proprietary fabrication technologies are able to prevent the triggering of unwanted autoimmune responses, which helps to overcome the blood-brain barrier and effectively deliver the medicine to the brain, the company said.
Apart from its controlling stake in the joint venture, TTY Biopharm said that it also controls the proprietary manufacturing process and therefore has a significant claim on any profits the drug makes.
The company’s net income in the first quarter dropped 21.35 percent year-on-year to NT$221 million (US$7.34 million), while sales rose 3.61 percent annually to NT$946 million over the period. Earnings per share were NT$0.89.
TTY Biopharm shares yesterday gained 0.49 percent to NT$102.5, outperforming the 0.05 percent fall of the TPEX, the local bourse for firms with small and medium capitalization, the market’s data showed.
The domestic unit of the Chinese-owned, Dutch-headquartered chipmaker Nexperia BV will soon be able to produce semiconductors locally within China, according to two company sources. Nexperia is at the center of a global tug-of-war over critical semiconductor technology, with a Dutch court in February ordering a probe into alleged mismanagement at the company. The geopolitical tussle has disrupted supply chains, with some carmakers reportedly forced to cut production due to chip shortages. Local production would allow Nexperia’s domestic arm, Nexperia Semiconductors (China) Ltd (安世半導體中國), to bypass restrictions in place since October on the supply of silicon wafers — etched with tiny components to
Singapore-based ride-hailing and delivery giant Grab Holdings Ltd has applied for regulatory approval to acquire the Taiwan operations of Germany-based Delivery Hero SE's Foodpanda in a deal valued at about US$600 million. Grab submitted the filing to the Fair Trade Commission on Friday last week, with the transaction subject to regulatory review and approval, the company said in a statement yesterday. Its independent governance structure would help foster a healthy and competitive market in Taiwan if the deal is approved, Grab said. Grab, which is listed on the NASDAQ, said in the filing that US-based Uber Technologies Inc holds about 13 percent of
Taiwan is open to joining a global liquefied natural gas (LNG) program if one is created, but on the condition that countries provide delivery even in a scenario where there is a conflict with China, an energy department official said yesterday. While Taiwan’s priority is to have enough LNG at home, the nation is open to exploring potential strategic reserves in other countries such as Japan or South Korea, Energy Administration Deputy Director-General Chen Chung-hsien (陳崇憲) said. While the LNG market does not have a global reserve for emergencies like that of oil, the concept has been raised a few times —
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday received government approval to deploy its advanced 3-nanometer (3nm) process at its second fab currently under construction in Japan, the Ministry of Economic Affairs said in a news release. The ministry green-lit the plan for the facility in Kumamoto, which is scheduled to start installing equipment and come online in 2028 with a monthly production capacity of 15,000 12-inch wafers, the ministry said. The Department of Investment Review in June 2024 authorized a US$5.26 billion investment for the facility, slated to manufacture 6- to 12nm chips, significantly less advanced than 3nm process. At a meeting with
RSS